🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 67577C105 (prev. 43358V109 )
- Market Cap
- Small Cap · $124 Million
- IPO
- 12/2/2014 · $11.00/share
- Previous Symbol
- HSGX (changed 10/4/2019)
- Previous Name
- Histogenics Corp.
Business: Ocugen, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases.
Notes: April 8, 2019 -- Histogenics Corporation and Ocugen, Inc. announced that they have entered into a definitive merger agreement under which the stockholders of Ocugen will become the majority owners of Histogenics’ outstanding common stock upon the close of the merger. The proposed merger will result in a combined publicly-traded, clinical-stage biopharmaceutical company operating under the Ocugen name. Ocugen, Inc. is a privately held, clinical-stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases.
Company Contact
- CEO
- Shankar Musunuri
- CFO
- Sanjay S. Subramanian
- Headquarters
- 5 Great Valley Parkway, Suite 160 Malvern PA 19355
- Phone
- 484-328-4701
- Investor Relations
- Kelly Beck · 484-328-4698 · kelly.beck@ocugen.com